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Abstract
Essential tremor (ET) is the most common pathological tremor in humans. The traditional view of
ET, as a mono-symptomatic condition, is being replaced by an appreciation of the spectrum of clinical
features, with both motor and non-motor elements. These features are not distributed homogeneously
across patients. In addition, post-mortem studies are now demonstrating distinct structural changes
in ET. There is growing evidence that ET may be a family of diseases rather than a single entity.
Further, this aging-associated, progressive disorder is associated with neuronal loss and postmortem
changes that occur in traditional neurodegenerative disorders.
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Introduction to Essential Tremor and Questions Posed
Essential tremor (ET), the commonest pathological tremor in humans, is among the more
ubiquitous neurological diseases, with a prevalence (age !40 years) of 4.0%.1, 2 Its most
recognizable clinical feature is an 8–12 Hz kinetic tremor of the arms (i.e., tremor during
voluntary movement)(Figure 1), which often is later accompanied by head and voice tremors.
The condition is global, affecting human beings in a variety of settings, ranging from the remote
Okapa sub-district of Papua New Guinea to the urban Washington Heights-Inwood community
in northern Manhattan, New York.1, 2 The traditional view of ET as a mono-symptomatic
condition characterized only by kinetic or postural tremor has been supplanted in recent years.
First, the tremor phenomenology is broad and many patients have other motor
manifestations3 and non-motor features, including cognitive and psychiatric.3, 4 Furthermore,
this expanded constellation of clinical features is not distributed homogeneously across
patients. For example, some patients develop head tremor while others do not. Some dement
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while others do not; some develop Parkinson’s disease (PD) while others do not.5 Recent
studies of the pathology of ET have demonstrated several distinctive structural changes,
including neuronal loss.6–10 With evidence of clinical and pathological heterogeneity
emerging, several important questions arise. First, is ET a single disease entity or a family of
diseases? Second, is ET neurodegenerative?
Essential Tremor or the Essential Tremors?
Neurology is replete with historical examples in which clinical-pathological investigations
have resulted in the partitioning of disease entities and the refinement of classification. For
example, many patients with upper motor neurons signs were clinically lumped together, yet
in the 1800s, Charcot and others, observed that among such patients who had sclerosis on
postmortem examination, one sub-group had a pattern that could be characterized as
‘amyotrophic lateral sclerosis’ (ALS) while a second sub-group had a pattern that could be
characterized as ‘multiple sclerosis’ (MS). We now know that ALS and MS are different
diseases with distinct mechanisms, clinical features, and treatments. Likewise, in the mid-
twentieth century, advances in neuropathology and careful clinical-pathological studies re-
defined the concept of parkinsonism as a family of disease entities rather than a single disease.
Idiopathic Parkinson’s disease (PD) could be distinguished from other entities such as
progressive supranuclear palsy and corticobasal ganglionic degeneration. It is conceivable that
we are now arriving at such a primary juncture in our understanding of ET. Evidence of clinical
heterogeneity and pathological heterogeneity is emerging, raising the question as to whether
it is possible to re-formulate ET as a cluster of separable clinical-pathological entities, that is,
a family of diseases – “the essential tremors”.
Heterogeneity (Clinical, Therapeutic Response, Pathological, and
Etiological)
Although clinical phenotypic variability by itself is not an argument for separate diseases, its
presence further opens that possibility. Clinically, the view of ET as a single neurological sign
no longer seems tenable. First, the tremor phenomenology itself is multifaceted. Although
kinetic and postural tremors are the core features upon which diagnostic criteria are generally
based (Table 1), intention tremor,11 and tremor at rest12 may also occur in subsets of patients.
The relative severity of different tremor types (kinetic > postural 13), the favored sites of
anatomical involvement (arm more often than head, and head more often than jaw 14), and the
typical direction of spread over time (from arms to head rather than the converse)15 are
distinctive, adding a degree of subtlety and complexity to the recognition and diagnosis of a
disorder that is often viewed as relatively ordinary and featureless. Indeed, perhaps due to a
lack of familiarity with these features, mis-diagnosis is exceedingly common; 30–50% of
patients diagnosed with ET do not have ET,16 which may make this one of the most commonly
mis-diagnosed neurological disorders. Moreover, kinetic tremor of the arms, though not the
head, may be a side-effect of many medications, which further contributes to this diagnostic
difficulty (Table 2). There are motor features aside from tremor. In a large number of studies,
11, 17 postural instability and mild to moderate gait ataxia, beyond that observed in normal
aging, have been demonstrated in subgroups of ET patients. In addition to these gait problems,
eye motion abnormalities (impaired smooth pursuit initiation and pathological suppression of
the vestibulo-ocular reflex time constant) were recently described in a study of 17 ET cases.
18 Third, there is a growing appreciation of the existence of a variety of non-motor features,
including cognitive, psychiatric, and sensory. Cognitive features, especially mild problems
with executive function and memory, were first reported in 200119 and soon after by numerous
other investigators.20 Furthermore, a population-based study in Madrid21 first demonstrated
in 2006 that the odds of prevalent dementia were nearly twice as high among the subset of ET
cases with older onset disease when compared with age-matched controls. The same group
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later demonstrated 5 that the risk of developing incident dementia was nearly twice as high in
the ET cases than controls. Also, a number of psychiatric correlates have been observed. The
presence of specific personality traits22, 23 has been demonstrated. In one such study, 22 the
observed personality profile was not related to functional disability or tremor severity,
suggesting that it could be a primary disease feature rather than a response to disabling tremor.
22 Anxiety,24 depressive symptoms,25 and social phobia 26 have been shown to occur in ET
patients more often than in controls. Traditionally, these have been viewed as psychiatric
responses to disabling tremor. Yet in one recent prospective study,4 depressive symptoms
preceded the onset of the tremor by several years (i.e., the presence of baseline self-reported
depression was associated with an increased risk of developing incident ET during follow-up).
Sensory abnormalities, including olfactory deficits in some studies27 and hearing loss in others,
28 have been reported in ET cases compared with age-matched controls, further drawing
attention to the domain of non-motor manifestations. Although a single disease may be have
a broad array of clinical manifestations (e.g., Huntington’s disease), such clinical variety can
also be an indication that one is dealing with a group of diseases (e.g., parkinsonisms such as
PD, progressive supranuclear palsy, and corticobasal ganglionic degeneration).
It is important to emphasize that these clinical features are heterogeneously distributed across
ET patients. Although some patterns are now becoming apparent (e.g., patients with intention
tremor have more gait difficulties and eye motion abnormalities,18 patients with rest tremor
generally have longstanding disease with severe kinetic tremor,12 dementia is associated with
older age of onset of ET,5 older age of onset and unilateral onset are associated with more rapid
progression29, 30), a clear separation of distinct clinical subtypes has yet to emerge.
The mainstays of therapy for ET are propranolol and primidone, although several promising
new agents have been introduced in recent years (Table 3); surgical treatment (deep brain
stimulation) is also highly effective.3 One re-occurring feature of pharmacotherapeutic trails
in ET is that the response to a particular medication is usually patchy, with approximately one-
half of the patients evidencing some degree of tremor reduction and others none at all;31 this
phenomenon is frequently observed by practitioners as well. Among other possibilities (e.g.,
differences in disease duration across treated patients), this heterogeneity of response could be
a marker of different underlying disease mechanisms in subsets of patients, although this
remains to be demonstrated.
Disease mechanisms in ET have been elusive. Despite its high prevalence, until recently, few
ET brains were examined and little information was available about the pathology. An intensive
effort was launched in 2003 to bank ET brains.6 In contrast with previous studies, these brains
were systematically examined to quantify cerebellar and other brainstem pathologies and were
compared to control brains. These analyses, based on 33 ET brains, indicated that the structural
pathological changes appeared to be of two types.6, 7, 9, 32 Most commonly (75%), brains were
characterized by clear cerebellar degenerative changes, including a 40% reduction in number
of Purkinje cells, a six-fold increase numbers of torpedoes (i.e., swellings of the Purkinje cell
axon that likely represent a cellular response to injury), and Purkinje cell heterotopia and
dendrite swellings. These brains did not have Lewy bodies. The remaining brains were
characterized by Lewy bodies confined mainly to the locus ceruleus with relative to total
sparing of other brainstem structures (see Table 2 in6). The prevalence of Lewy bodies was
significantly greater than that observed in similarly-aged controls, indicating that they were
not likely to be incidental.6 Furthermore, this particular pattern of Lewy body involvement in
ET has not been described in series of “atypical” Lewy body brains (i.e., brains that do not
follow the Braak staging scheme).33 The ET brains with Lewy bodies did not have excessive
torpedoes or Purkinje cell loss.6 These two pathological patterns were labeled “cerebellar ET”
and “Lewy body variant of ET” [LBVET]).6, 34 Other recent series of ET brains have also
confirmed a heterogeneous pathology involving Purkinje cell loss in the cerebellum in some
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cases and changes, including cell loss, in the locus ceruleus in others.8 These recent postmortem
studies have helped identify degenerative structural alterations in the cerebellum and its
connecting pathways in ET. How changes in the locus ceruleus could produce ET is less clear,
although neurons of the locus ceruleus synapse with cerebellar Purkinje cell dendrites.35 These
projections are important for the normal development and maintenance of Purkinje cells.36
Impaired activity in the locus ceruleus could result in a diminution of stimulatory output from
that locus to the Purkinje cells.
On an etiological level, ET is often considered to be genetic.37 There are many examples of
families in which the proband and multiple relatives have ET and in which the pattern of
inheritance is consistent with an autosomal dominant model. In 1997, linkage was
demonstrated to a region on chromosome 2p 38 and, in that same year, to chromosome 3q in
other families.39 A third study demonstrated linkage to a region on chromosome 6p in several
families.40 Aside from these three studies, other studies that have failed to demonstrate linkage
to these three regions, indicating that there will likely be more than three genes responsible for
this disease.37, 41 It is important to note, however, that the genetic studies have not progressed
further and the specific ET genes have been not yet been identified.37–40 In the absence of a
specific genotype for ET, there are as yet no specific genotype-phenotype correlations,
although is appears that young onset cases are generally familial (i.e., likely to have a genetic
susceptibility).42 Aside from genetic factors, there is also a growing understanding that
environmental factors are likely to contribute to the etiology of ET as well, indicating that there
is further heterogeneity on an etiological level. Several lines of evidence support the role of
these factors. First, while commonly stated that 50% or more of ET cases have a genetic basis,
the precise derivation of this estimate is unclear and its validity is also doubtful.43 Indeed, some
estimates are as low as 17%.43 In twin studies 44, 45 concordance in monozygotic twins was
only 60% in one study and 63% in another. Second, the well-known existence of intra-familial
differences in age of onset, location of tremor, and severity of tremor 46 also suggests that
environmental (or perhaps other genetic) factors may be serving as modifiers of underlying
susceptibility genotypes. In terms of environmental factors, a growing number of case-control
studies 47 has implicated several specific toxins, namely "-carboline alkaloids (e.g., harmine
and harmane, a group of highly tremorogenic dietary chemicals) and lead; and further studies
of these putative environmental toxins are needed.
Organizing the Heterogeneity
Information presented in the previous section may be organized by etiologies, pathologies and
the clinical features (Figure 2). Given the sheer prevalence and ubiquity of this condition, the
historical tendency to split disease entities as new knowledge arises, the appreciation of a
broader variety of clinical features in several separate domains (e.g., tremor, other motor,
cognitive, psychiatric), the observation that these are not uniformly present in ET patients, the
evidence that multiple genes will likely be responsible for this disease, and preliminary
evidence of distinct pathological patterns, it is likely that ET will turn out to be a family of
diseases rather than a single disease entity. It is likely that this family of diseases, united by
the presence of kinetic tremor, would be separable on the basis of etiological, clinical,
therapeutic response and pathological features, although further work is needed to explore these
relationships.
Is ET Neurodegenerative?
A question implicitly raised in the above discussion is whether this disease (or these diseases)
are neurodegenerative. The idea that ET could be neurodegenerative is not new. In 1948,
Critchley and Greenfield wrote: “Although anatomical proof is as yet lacking, there are at least
a number of clinical points to make question whether “essential tremor” may not, at times any
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rate, represent an incomplete or a premature variant of one of the cerebellar atrophies.”48
Although not further elaborated by those authors, these clinical points include its insidious
onset, association with advanced aging (i.e., both incidence and prevalence increase with
aging), gradual yet progressive nature, and the presence of “cerebellar” features (e.g., intention
tremor and ataxia) on examination.
Neurodegenerative diseases traditionally have been defined as diseases that begin insidiously,
pursue a gradually progressive course that may continue for many years, and are characterized
by the selective involvement of anatomically and physiologically related systems of neurons
due to intrinsic processes rather than an identifiable outside influence (e.g., vascular, auto-
immune). Cell loss is also considered by many to be a prominent feature of these diseases.49
Furthermore, their occurrence often increases markedly with advancing age. What is the
evidence that ET is neurodegenerative? The clinical points noted above are important. ET has
an insidious onset46, 50 and then follows a gradual yet progressive clinical course.29, 30 There
is a marked and continued rise in disease occurrence in advanced ages.1, 2 This clinical
constellation is somewhat compelling; however, none of these features in isolation is specific
to neurodegenerative diseases. On a tissue-based level, the evidence is more compelling.
Selective involvement of an anatomically and physiologically related system of neurons,
Purkinje cells, has been reported in ET cases both in our recent series (Figure 3)6, 7 and in the
other large recent series.8 When quantified using different methods, Purkinje cell loss is
significant. There is an approximate 40% loss of these cells compared to age-matched control
brains,6, 7 which persists even when one adjusts for age and other confounding pathologies
(e.g., mild Alzheimer’s type changes). Additional evidence that the Purkinje cells are diseased
is that there are significantly more torpedoes in the ET brain, where their numbers are six-times
higher than expected for age, and a preponderance of displaced (i.e., heterotopic) Purkinje cells
as well as Purkinje cells with dendritic swellings.6 In contrast to these cases, the ET cases with
normal cerebella have Lewy bodies,6, 9 which are lesions that have long been considered
important in the pathogenesis of another neurodegenerative tremor disorder, namely, PD.
While none of these pathological changes in the cerebellum are disease-specific (e.g., other
forms of cerebellar degeneration may be characterized by Purkinje cell loss and torpedo
formation), this just indicates that the changes seen in the cerebellum in ET occur more broadly
in the cerebellar degenerations. Aside from this structural-pathological evidence suggesting a
neurodegenerative process, other evidence suggests that ET is neurodegenerative. While many
of these features in isolation are not specific to neurodegenerative diseases, the constellation
of findings, all present in the same disease, is more compelling (Table 4). For example, there
is a longstanding clinical association between ET and PD; indeed, having ET increases the risk
of developing incident PD four to five-fold.51 Furthermore, having older onset ET increases
the risk of developing Alzheimer’s disease nearly two-fold.5 This association between ET and
subsequent development of these neurodegenerative diseases suggests that ET may share
pathogenic mechanisms with these disorders.
Conclusion
There is some evidence to suggest that ET is a family of diseases rather than a single entity
(Table 5). These disorders, perhaps better termed “the essential tremors”, are aging-associated,
progressive, and associated with cell loss and other types of changes (Lewy body formation)
that traditionally occur in neurodegenerative disorders. Future study is needed to continue to
shape our evolving notion of the entity that we currently refer to as “essential tremor”.
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Kinetic tremor is apparent in an ET patient’s drawing of an Archimedes spiral.
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The heterogeneity in ET may be organized by (1) disease etiology, (2) tissue-level changes
that occur after the disease process is initiated and as it develops, and (3) clinical features that
are the end product of these underlying pathological processes. Here is one such possible
schema.
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When quantified using different methods, Purkinje cell loss in ET is significant compared to
age-matched controls. Bielschowsky-stained section (50× magnification) of the cerebellar
cortex in a 79 year old ET case showing normal Purkinje cellularity (right) vs. a region with
segmental loss of Purkinje cells (left).
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Two sets of clinical diagnostic criteria for definite essential tremor. The Movement
Disorder Society has proposed consensus criteria for ET.52, 53 The Washington
Heights–Inwood Genetic Study of Essential Tremor criteria54 specify the minimal
severity of tremor that is required, and are also widely used in genetic and
epidemiological studies.1, 55–58
Consensus statement of the Movement Disorder Society on tremor52, 53
Inclusion criteria
1 Bilateral postural tremor with or without kinetic tremor, involving hands and forearms, that is visible and persistent
2 Duration greater than 5 years
Exclusion criteria
1 Other abnormal neurological signs (except Froment’s sign)
2 Presence of known causes of increased physiological tremor
3 Concurrent or recent exposure to tremorogenic drugs or the presence of a drug withdrawal state
4 Direct or indirect trauma to the nervous system within 3 months before the onset of tremor
5 Historical or clinical evidence of psychogenic origins
6 Convincing evidence of sudden onset or evidence of stepwise deterioration
Washington Heights Inwood Genetic Study of Essential Tremor criteria54
1 On examination, a +2 postural tremor* in at least one arm (a head tremor might also be present, but is not sufficient for the diagnosis)
2 On examination, there must be a +2 kinetic tremor during at least four tasks, or a +2 kinetic tremor on one task and a +3 kinetic tremor on a second
task. Tasks include pouring water, using a spoon to drink water, drinking water, finger-to-nose maneuver, and drawing spirals
3 If on examination the tremor is present in the dominant hand, then by report it must interfere with at least one activity of daily living (eating, drinking,
writing or using the hands). If on examination the tremor is not present in the dominant hand, then this criterion is irrelevant
4 Medications, hyperthyroidism, ethanol, and dystonia are not potential etiological factors
5 Symptoms are not psychogenic (e.g. bizarre features, features inconsistent in character, the patient is distractable, or other psychiatric features on
examination)
*
0 to +3 tremor ratings: 0, no visible tremor; +1, tremor is of low amplitude, barely perceivable, or intermittent; +2, tremor is of moderate amplitude (1–
2 cm) and usually present, and is clearly oscillatory; +3, tremor is of large amplitude (>2 cm), violent, and jerky, resulting in difficulty completing the
task because of spilling or inability to hold a pen to paper































































Medications used to treat ET
Medication Dosage Potential side effects
Acetazolamide Up to 500 mg/d Weakness, fatigue
Alprazolam 0.125–3 mg/d Sedation, fatigue, potential for abuse
Atenolol 50–150 mg/d Lightheadedness, nausea, cough, dry mouth, sleepiness
Botulinum toxin A (hand tremor) 50–100 U Hand/finger weakness, reduced grip strength, pain at injection site, stiffness, cramping, haematoma,
paraesthesias
Botulinum toxin A (head tremor) 40–400 U Neck weakness, post-injection pain
Botulinum toxin A (voice tremor) 0.6–15 U Breathiness, weak voice, swallowing difficulty
Clonazepam 0.5–6 mg/d Drowsiness
Clozapine Up to 200 mg/d Sedation, potential agranulocytosis (0.8% at one year)
Flunarizine 10 mg/d Sedation, weight gain, depression, dystonia, parkinsonism
Gabapentin 1,200–1,800 mg/d Lethargy, fatigue, decreased libido, dizziness, nervousness, shortness of breath
Levetiracetam Up to 3,000 mg/d Depressed mood, drowsiness, fatigue
Methazolamide Up to 300 mg/d Somnolence, nausea, paresthesias, headache
Nimodipine 120 mg/d Headache, heartburn
Nadolol 120–240 mg/d None
Olanzapine 20 mg/d Drowsiness, sedation, weight gain, diabetes
1-octanol 1 mg/kg/d Lethargy, asthenia, headache
Phenobarbital Up to 150 mg/d Drowsiness, fatigue ataxia
Pregabalin Up to 600 mg/d Dizziness, somnolence
Primidone Up to 750 mg/d Sedation, drowsiness, fatigue, nausea, giddiness, vomiting, ataxia, malaise, dizziness, unsteadiness,
confusion, vertigo, acute toxic reaction
Propranolol 60–800 mg/d Reduced arterial pressure, reduced pulse rate, tachycardia, bradycardia, impotency, drowsiness,
exertional dyspnoea, confusion, headache, dizziness
Long-acting propranolol 80–320 mg/d Skin eruption, transient dizziness
Sodium oxybate Up to 7.5 g/d Dizziness, headache, sedation, ataxia
Sotalol 75–200 mg/d Decreased alertness
Topiramate Up to 400 mg/d Appetite suppression, weight loss, paraesthesias, anorexia, concentration difficulties
Zonisamide Up to 200 mg/d Ataxia, dizziness, somnolence, agitation, anorexia
























Evidence suggesting that ET is neurodegenerative
Evidence Comment/Rationale PD* AD* Cautionary Caveat




related systems of neurons is
considered an important feature of
neurodegenerative disorders. Lewy
bodies are a feature of PD, a
neurodegenerative disease.
Yes Yes1 Additional postmortem studies are needed to confirm the results
of currently-emerging large postmortem series.6, 8
Clinical resemblance to other
cerebellar atrophies and Purkinje cell
loss
This suggests shared disease
mechanisms.
No No
Marked rise in occurrence with
advanced age
PD and AD are associated with
advanced age
Yes Yes
Clinically progressive in most patients PD and AD are relentlessly
clinically-progressive
Yes Yes Diseases that are not neurodegenerative may sometimes be
clinically-progressive.
Somatotopic spread of tremor over time Tremor often begins in one body
region, and as the disease worsens,
spreads to others.
Yes Yes2
Olfactory Deficit Olfactory deficits are reported in
PD and AD
Yes Yes Not specific to neurodegenerative disorders.
Not a consistent finding across all studies of ET.
Loss of body mass index59 Neurodegnerative diseases are
often associated with loss of body
mass index
Yes Yes Not specific to neurodegenerative disorders.
Not a consistent finding across all studies of ET.
Increased risk of mortality60 Neurodegenerative disorders are
associated with increased risk of
mortality
Yes Yes Not specific to neurodegenerative disorders.
Not a consistent finding across all studies of ET.
Increased risk of AD This association with ET suggests




Increased risk of PD This association with ET suggests





This feature or a similar feature is a characteristic of PD or AD.
AD = Alzheimer’s disease, PD = Parkinson’s disease, ET = essential tremor
1
Neuronal loss in the hippocampus and neocortex are features of AD.
2
As AD progresses, different cortical regions may become involved.

























• Essential tremor (ET), a progressive disorder of the central nervous system, traditionally has been characterized by kinetic tremor of the arms.
• This view of ET as a mono-symptomatic condition has been supplanted in recent years. Evidence of clinical heterogeneity and pathological
heterogeneity is emerging, raising the question as to whether it is possible to re-formulate ET as a cluster of separable clinical-pathological entities,
that is, a family of diseases – “the essential tremors”.
• The tremor phenomenology is broad and many patients have other motor manifestations and non-motor features, including cognitive and psychiatric.
Furthermore, this expanded constellation of clinical features is not distributed homogeneously across patients.
• Differences in therapeutic response phenotype provide yet another example of clinical heterogeneity and this could be a marker of different
underlying disease mechanisms in subsets of patients.
• Disease mechanisms in ET have been elusive, yet recent postmortem studies have demonstrated a heterogeneous pathology, with ET cases clustered
into two groups: those with cerebellar degenerative changes (“cerebellar ET”), and those with brainstem Lewy bodies (“Lewy body variant of ET”).
• The etiology of ET is often genetic; although specific genes associated with ET have not yet been identified, susceptibility loci have been found on
chromosomes 3q, 2p and 6p. Also, several environmental toxins, including harmane and lead, have been tentatively linked with ET.
• ET is aging-associated, progressive, and associated with neuronal loss and other types of changes that traditionally occur in neurodegenerative
disorders, indicating that ET is likely to be a neurodegenerative disease.
• The mainstays of therapy for ET are propranolol and primidone, although several promising new agents have been introduced in recent years.
Surgical treatment (deep brain stimulation) is also highly effective.
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